News
Multiple Sclerosis
Scope 66 - Why do some people respond better to MS treatment...
A recent exploratory trial looking at the effect of the drug MIS416 on patients has f...
Scope 65 - Great New Zealand Trek 2018: Stage 13 completed
More than 400 participants and support crew descended on the picturesque Central ...
Scope 64 - Research in focus: Multiple Sclerosis
The Multiple Sclerosis team has been working with a New Zealand biomedical company...
Scope 63 - Optimizing the use of antipsychotic medicines for...
Professor Anne La Flamme and her Multiple Sclerosis (MS) research group recently publ...
The Great New Zealand Trek: 9 Years and more than NZ$250,000...
With an impressive 238 participants taking part this year, it’s been another successf...
The Great New Zealand Trek has raised almost a quarter of a ...
Over the last 8 years, The Great New Zealand Trek has donated $245,000 to help find a...
Research Report 2016 - Multiple sclerosis
A Phase Ib/IIa suitability and acceptability trial of two antipsychotic medicines, cl...
Funding brings Multiple Sclerosis clinical trial closer
The journey to deliver a new (and first-ever) treatment for secondary progressive MS ...
MS drug research featured on ONE News
On Thursday night, 14 August 2014, Dr Anne La Flamme's latest Multiple Sclerosis rese...
Camaraderie, countryside and commitment to beat Multiple Scl...
Its not often a holiday combines walking, horse riding or mountain biking through so...